Raymond James analyst, Elliot Wilbur,reiterated his Strong Buy rating on Flexion Therapeutics (NASDAQ: FLXN) after taking CEO, Michael Clayman, CFO ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE